Project Grant R21CA317184
Award Date 7/21/26
Completion Date 6/30/28
Dollars Obligated $396K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55455, USA
Similar Awards
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $617,486 to ST Jude Children's Research Hospital Inc. on March 13, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393). The research investigates how chimeric transcription factors, specifically PAX3-FOXO1 and PAX7-FOXO1 fusion oncoproteins, suppress intrinsic innate immune responses in alveolar rhabdomyosarcoma (ARMS), an aggressive childhood soft...
- The National Cancer Institute awarded St. Jude Children's Research Hospital Graduate School of Biomedical Sciences, LLC $146,190 on December 1, 2025, under the Cancer Research Manpower program (CFDA 93.398) to investigate the mechanisms of rhabdomyosarcoma transformation from non-myogenic cell origins. The award funds research defining chromatin landscape changes during fusion-negative rhabdomyosarcoma (FN-RMS) transformation and identifying transcription factors required for...
- The National Cancer Institute awarded the Regents of the University of Minnesota $573,262 on April 17, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop autologous humanized leukemia models for immunotherapy testing. The recipient will generate patient-derived xenograft models using paired leukemia and immune cells from the same pre-B acute lymphoblastic leukemia patient, addressing a gap in preclinical testing where current models either lack functional immune systems...
- The National Cancer Institute awarded New York University $716,681 on May 22, 2026, under the Cancer Biology Research program (CFDA 93.396) to fund research into understanding and therapeutically targeting myeloid sarcoma, an extramedullary subtype of acute myeloid leukemia characterized by solid tumor-like invasive masses at multiple anatomical sites and dismal survival outcomes below 20% at five years. The funded research builds on the recipient's prior transcriptomic, genomic, and spatial...
- The National Cancer Institute awarded the Regents of the University of Minnesota $626,943 on July 3, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate primary cilia as metabolic regulators in cholangiocyte health and disease. The research targets understanding how ciliary defects in bile duct cells drive metabolic reprogramming and contribute to cholangiocarcinoma progression, and aims to develop ciliotherapy-based treatments to restore ciliary function. The project...
- The National Cancer Institute, a division of the Department of Health and Human Services, awarded the Regents of the University of Minnesota $650,590 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to elucidate properties of T cell receptors that govern pancreatic cancer immunotherapy response. The funded research investigates how T cells function within the pancreatic tumor microenvironment and respond to immunotherapy, with a focus on T cell receptor (TCR) features...
- The National Cancer Institute awarded the Regents of the University of Minnesota $141,016 on December 1, 2025, under the Cancer Research Manpower program (CFDA 93.398) to conduct structural studies of APOBEC3A and APOBEC3B enzymes and their inhibition mechanisms. The project, titled "Deciphering APOBEC Inhibition: Unraveling Structural Dynamics via Viral Protein and Nanobody Interactions," runs through June 30, 2027, with work performed in Minneapolis, Minnesota. Aim 1 uses...
- The National Cancer Institute (NCI), part of the Department of Health and Human Services, awarded $628,073 to St. Jude Children's Research Hospital Inc. on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to mechanistically dissect and target non-cell autonomous tumor promotion in DICER1 cancer predisposition. The project investigates how germline heterozygous loss-of-function mutations in DICER1, a ribonuclease III enzyme essential for processing microRNAs, drive...
- The National Cancer Institute awarded the Research Institute At Nationwide Children's Hospital $146,779 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate metastatic tumor microenvironmental mechanisms in osteosarcoma and develop novel therapeutic approaches. The funded research identifies mechanisms underlying metastatic establishment in osteosarcoma by examining interactions between epithelial cells, macrophages, and tumor cells within the...
- The National Cancer Institute, a division of the National Institutes of Health under the Department of Health and Human Services, awarded $134,000 to the University of Massachusetts Medical School on September 3, 2026, under the Cancer Biology Research program (CFDA 93.396). The recipient will conduct research employing genetically engineered mouse models to elucidate mechanisms by which loss of CAMK2B (calcium/calmodulin-dependent protein kinase II beta) promotes metastasis and immune...